The global antifungal drugs market size accounted for USD 17.39 billion in 2024, grew to USD 18 billion in 2025 and is expected to be worth around USD 24.51 billion by 2034, registering a CAGR of 3.49% between 2024 and 2034. The North America antifungal drugs market size is calculated at USD 7.30 billion in 2024 and is estimated to grow at a CAGR of 3.49% during the forecast period.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Antifungal Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Antifungal Drugs Market, by Drug Class, 2024-2034
8.1.1 Echinocandins
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Azoles
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Allylamines
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Polyenes
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2021-2034)
9.1. Antifungal Drugs Market, by Indication, 2024-2034
9.1.1. Aspergillosis
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Dermatophytosis
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Candidiasis
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2021-2034)
10.1. Antifungal Drugs Market, by Infection Type, 2024-2034
10.1.1. Systemic Antifungal Infections
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Superficial Antifungal Infections
10.1.2.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.1.2. Market Revenue and Forecast, by Indication (2021-2034)
11.1.3. Market Revenue and Forecast, by Infection Type (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Indication (2021-2034)
11.1.4.3. Market Revenue and Forecast, by Infection Type (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Indication (2021-2034)
11.1.5.3. Market Revenue and Forecast, by Infection Type (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.2. Market Revenue and Forecast, by Indication (2021-2034)
11.2.3. Market Revenue and Forecast, by Infection Type (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Indication (2021-2034)
11.2.4.3. Market Revenue and Forecast, by Infection Type (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Indication (2021-2034)
11.2.5.3. Market Revenue and Forecast, by Infection Type (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Indication (2021-2034)
11.2.6.3. Market Revenue and Forecast, by Infection Type (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Indication (2021-2034)
11.2.7.3. Market Revenue and Forecast, by Infection Type (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.2. Market Revenue and Forecast, by Indication (2021-2034)
11.3.3. Market Revenue and Forecast, by Infection Type (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Indication (2021-2034)
11.3.4.3. Market Revenue and Forecast, by Infection Type (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Indication (2021-2034)
11.3.5.3. Market Revenue and Forecast, by Infection Type (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Indication (2021-2034)
11.3.6.3. Market Revenue and Forecast, by Infection Type (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Indication (2021-2034)
11.3.7.3. Market Revenue and Forecast, by Infection Type (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.2. Market Revenue and Forecast, by Indication (2021-2034)
11.4.3. Market Revenue and Forecast, by Infection Type (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Indication (2021-2034)
11.4.4.3. Market Revenue and Forecast, by Infection Type (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Indication (2021-2034)
11.4.5.3. Market Revenue and Forecast, by Infection Type (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Indication (2021-2034)
11.4.6.3. Market Revenue and Forecast, by Infection Type (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Indication (2021-2034)
11.4.7.3. Market Revenue and Forecast, by Infection Type (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.5.2. Market Revenue and Forecast, by Indication (2021-2034)
11.5.3. Market Revenue and Forecast, by Infection Type (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Indication (2021-2034)
11.5.4.3. Market Revenue and Forecast, by Infection Type (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Class (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Indication (2021-2034)
11.5.5.3. Market Revenue and Forecast, by Infection Type (2021-2034)
12.1. Pfizer, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Novartis AG
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Sanofi
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. GlaxoSmithKline plc
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bayer AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Glenmark
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Abbott
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. AstellasPharma, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Enzon Pharmaceuticals, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample